Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
BMS combination cures 90% of genotype 1b hepatitis C in 24 weeks

A combination of two direct-acting antivirals developed by Bristol–Myers Squibb cured 90% of previously untreated people with genotype 1b hepatitis C infection in 24 weeks, without the

Published
Less than 1 hour ago
By
Keith Alcorn
Sofosbuvir + ribavirin is safe and effective for people with hepatitis C who have advanced liver disease

Sofosbuvir plus ribavirin is a safe option that can lead to sustained response in people with advanced liver disease including those with decompensated cirrhosis and portal hypertension, and

Published
15 hours ago
By
Liz Highleyman
AbbVie 3-drug combination cures 92 to 96% of hepatitis C patients with cirrhosis

The largest study of new direct-acting antivirals yet conducted in people with hepatitis C genotype 1 who have compensated cirrhosis has shown that it is possible to

Published
15 April 2014
By
Keith Alcorn
AbbVie 2-drug combination + ribavirin achieves 100% cure in previously untreated genotype 4 hepatitis C

A combination of two direct-acting antivirals developed by AbbVie cured 100% of previously untreated patients with hepatitis C genotype 4 infection when used with ribavirin, Christophe Hézode

Published
14 April 2014
By
Keith Alcorn
Sofosbuvir/ledipasvir co-formulation cures more than 90% of treatment-naive and retreated genotype 1 patients

A co-formulation of sofosbuvir and ledipasvir taken for as little as eight to twelve weeks produced high sustained response rates across the board for participants in the

Published
14 April 2014
By
Liz Highleyman
Sofosbuvir + simeprevir dual therapy shows high cure rates for hepatitis C patients with or without cirrhosis

A 12-week oral regimen of sofosbuvir (Sovaldi) plus simeprevir (Olysio) without pegylated interferon or ribavirin led to sustained virological response in 93% of people with genotype

Published
14 April 2014
By
Liz Highleyman
European liver specialists recommend 'mix-and-match' approach to new hepatitis C drugs

The European Association for the Study of the Liver (EASL) has issued new guidelines for the treatment of hepatitis C which recommend that wherever possible,

Published
11 April 2014
By
Keith Alcorn
Sofosbuvir/ledipasvir produces early cure for 100% of people with HIV and HCV co-infection

Treatment for 12 weeks with a co-formulation of sofosbuvir and ledipasvir led to sustained response for all participants with HIV and HCV co-infection who had genotype 1

Published
11 April 2014
By
Liz Highleyman
Sofosbuvir/ledipasvir is safe and effective for relapsers and hard-to-treat patients

A co-formulation of sofosbuvir and ledipasvir successfully treated a variety of difficult-to-treat patient populations including people with hepatitis C virus (HCV) genotype 3, people with decompensated cirrhosis and

Published
11 April 2014
By
Liz Highleyman
88% of previous relapsers achieve hepatitis C cure with simeprevir-based triple therapy

Almost 90% of European patients who had relapsed after previous treatment with pegylated interferon and ribavirin were cured of hepatitis C after 24 weeks of treatment with

Published
10 April 2014
By
Keith Alcorn
← First12345...46Next →

Filter by country